ethyl 5-amino-6,7-difluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylate | 181942-15-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl 5-amino-6,7-difluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylate
• 英文别名: ethyl 5-amino-6,7-difluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylate；ethyl 5-amino-6,7-difluoro-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylate；ethyl 5-amino-6,7-difluoro-1-[(1R,2S)-2-fluorocyclopropyl]-8-methyl-4-oxoquinoline-3-carboxylate
• CAS: 181942-15-4
• 化学式: C₁₆H₁₅F₃N₂O₃
• 分子量: 340.302
• InChiKey: KUQMLBKXKBNVAF-DTWKUNHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  72.6
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  ethyl 5-amino-6,7-difluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylate 在 盐酸 、 溶剂黄146 、 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 1.0h， 生成 5-Amino-7-[(R)-4-(1-tert-butoxycarbonylamino-cyclopropyl)-3,3-difluoro-pyrrolidin-1-yl]-6-fluoro-1-((1R,2S)-2-fluoro-cyclopropyl)-8-methyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of 5-Amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic Acid Antibacterials Having Fluorinated 7-[(3R)-3-(1-Aminocyclopropan-1-yl)pyrrolidin-1-yl] Substituents

  摘要：

  A series of novel 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolones bearing fluorinated (3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl substituents at the C-7 position (2-4) was synthesized to obtain potent drugs for infections caused by Gram-positive pathogens, which include resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), and vancomycin-resistant enterococci (VRE). These fluorinated compounds 2-4 exhibited potent antibacterial activity comparable with that of a compound bearing a non-fluorinated (3R)-3-(1-aminocyclopropan-1-yl)pyrrolidine moiety at the C-7 position (1) and had at least 4 times more potent activity against representative Gram-positive bacteria than ciprofloxacin (CPFX), gatifloxacin (GFLX), or moxifloxacin (MFLX). Among them, the 7-[(3S,4R)-4-(1-aminocyclopropan-1-yl)-3-fluoropyr-rolidin-1-yl] derivative 3 (=DQ-113), which showed favorable profiles in preliminary toxicological and nonclinical pharmcokinetic studies, exhibited potent antibacterial activity against clinically isolated resistant Gram-positive pathogens.

  DOI：

  10.1021/jm020328y
• 作为产物：
  描述：

  ethyl (2,4,5-trifluoro-3-methyl-6-nitrobenzoyl)acetate 在 氢气 、 乙酸酐 、 镍 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 5.17h， 生成 ethyl 5-amino-6,7-difluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylate
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of 5-Amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic Acid Antibacterials Having Fluorinated 7-[(3R)-3-(1-Aminocyclopropan-1-yl)pyrrolidin-1-yl] Substituents

  摘要：

  A series of novel 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolones bearing fluorinated (3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl substituents at the C-7 position (2-4) was synthesized to obtain potent drugs for infections caused by Gram-positive pathogens, which include resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), and vancomycin-resistant enterococci (VRE). These fluorinated compounds 2-4 exhibited potent antibacterial activity comparable with that of a compound bearing a non-fluorinated (3R)-3-(1-aminocyclopropan-1-yl)pyrrolidine moiety at the C-7 position (1) and had at least 4 times more potent activity against representative Gram-positive bacteria than ciprofloxacin (CPFX), gatifloxacin (GFLX), or moxifloxacin (MFLX). Among them, the 7-[(3S,4R)-4-(1-aminocyclopropan-1-yl)-3-fluoropyr-rolidin-1-yl] derivative 3 (=DQ-113), which showed favorable profiles in preliminary toxicological and nonclinical pharmcokinetic studies, exhibited potent antibacterial activity against clinically isolated resistant Gram-positive pathogens.

  DOI：

  10.1021/jm020328y

文献信息

• Pyridonecarboxylic acid derivatives substituted by a bicyclic amino
  申请人：Daiichi Pharmaceutical Co., Ltd.

  公开号：US05849757A1

  公开（公告）日：1998-12-15

  This invention relates to a N.sub.1 -(halogenocyclopropyl)-substituted pyridonecarboxylic acid derivative represented by the following formula (I): ##STR1## wherein X.sup.1 is a halogen atom or a hydrogen atom; X.sup.2 is a halogen atom; R.sup.1 is a hydrogen atom, a hydroxyl group, a thiol group, a halogenomethyl group, an amino group, an alkyl group or an alkoxy group which may have a substituent group; R.sup.2 is a group represented by the following formula (II): ##STR2## wherein R.sup.3 and R.sup.4 are independently a hydrogen atom or an alkyl group and n is an integer of 1 or 2; A is a nitrogen atom or a partial structure of the following formula (III): ##STR3## wherein X.sup.3 is a hydrogen atom, a halogen atom, a cyano group, an amino group, an alkyl group, a halogenomethyl group, an alkoxyl group or a halogenomethoxyl group which may have a substituent group; and R is a hydrogen atom, a phenyl group, an acetoxymethyl group, a pivaloyloxymethyl group, an ethoxycarbonyl group, a choline group, a dimethylaminoethyl group, a 5-indanyl group, a phthalidynyl group, a 5-alkyl-2-oxo-1,3-dioxol-4-ylmethyl group, a 3-acetoxy-2-oxobutyl group, an alkyl group, an alkoxymethyl group or a phenylalkyl group, and provides a heterocyclic compound useful as antibacterial drugs.

  这项发明涉及一种由以下式（I）表示的N.sub.1-(卤代环丙基)-取代吡啶酮羧酸衍生物：其中X.sup.1是卤素原子或氢原子；X.sup.2是卤素原子；R.sup.1是氢原子、羟基、硫醇基、卤代甲基基团、氨基、烷基或可能具有取代基团的烷氧基；R.sup.2是由以下式（II）表示的基团：其中R.sup.3和R.sup.4独立地是氢原子或烷基，n是1或2的整数；A是氮原子或以下式（III）的部分结构：其中X.sup.3是氢原子、卤素原子、氰基、氨基、烷基、卤代甲基基团、烷氧基或可能具有取代基团的卤代甲氧基；R是氢原子、苯基、乙酰氧甲基基团、戊酰氧甲基基团、乙氧羰基、胆碱基团、二甲氨基乙基基团、5-茚基团、邻苯二酰基团、5-烷基-2-氧代-1,3-二氧杂环戊-4-基甲基基团、3-乙酰氧基-2-氧代丁基基团、烷基、烷氧甲基或苯基烷基基团，并提供一种用作抗菌药物的杂环化合物。
• Process for producing quinolonecarboxlic acids and intermediates thereof
  申请人：——

  公开号：US20030060631A1

  公开（公告）日：2003-03-27

  This invention relates to methods for the efficient production of quinolonecarboxylic acid based synthetic antibacterial agents which are expected for applications such as excellent medicaments and agricultural chemicals and to intermediate compounds to be used therein. According to the present invention, an amine substituent as the 7-position substituent of the quinolonecarboxylic acid derivative can be efficiently introduced.

  该发明涉及一种高效生产基于喹诺酮羧酸的合成抗菌剂的方法，这些抗菌剂可用于优良的药物和农业化学品等应用，并涉及用于其中的中间化合物。根据本发明，可以有效地引入喹诺酮羧酸衍生物的7位取代基作为胺基取代基。
• PROCESS FOR PRODUCING QUINOLONECARBOXYLIC ACIDS AND INTERMEDIATES THEREOF
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1258478A1

  公开（公告）日：2002-11-20

  This invention relates to methods for the efficient production of quinolonecarboxylic acid based synthetic antibacterial agents which are expected for applications such as excellent medicaments and agricultural chemicals and to intermediate compounds to be used therein. According to the present invention, an amine substituent as the 7-position substituent of the quinolonecarboxylic acid derivative can be efficiently introduced.

  本发明涉及高效生产喹啉羧酸类合成抗菌剂的方法，这种抗菌剂有望应用于优良的药物和农用化学品等领域，本发明还涉及其中使用的中间化合物。根据本发明，可以有效地引入胺取代基作为喹啉羧酸衍生物的 7 位取代基。
• HETEROCYCLIC COMPOUNDS
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP0807630B1

  公开（公告）日：2003-05-07
• Pyridonecarboxylic acid derivatives and their use as antibacterial agents
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1304329B1

  公开（公告）日：2008-10-15